ArticleJournal of cancer research and clinical oncology2026
Interpreting the apparent benefit of thoracic radiotherapy in metastatic NSCLC: patient selection and analytical issues remain important-a comment on Xue et al.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thoracic radiotherapy (TRT) has been proposed as a potentially beneficial adjunct to first-line targeted therapy or chemoimmunotherapy in metastatic non-small cell lung cancer (NSCLC). This commentary discusses the retrospective study by Xue et al. and highlights several methodological issues that may influence interpretation of the reported survival benefit. Although the observed improvement in overall survival is clinically encouraging, imbalances in metastatic burden, inconsistent incorporation of key prognostic variables, and limited maturity of survival data may introduce residual confounding. Additional concerns include the causal interpretation of multivariable models, overlapping definitions of pulmonary toxicity, time-dependent adverse events, and unadjusted subgroup analyses. Overall, TRT may benefit carefully selected patients, but prospective studies and robust real-world analyses using causal-inference methods are needed to define optimal candidates and ensure safe implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.